Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07330674 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
A Phase 1 study of Age Related Macular Degeneration (ARMD) and AMD - Age-Related Macular Degeneration, sponsored by Aptabio Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT07330674 is a Phase 1 study of Age Related Macular Degeneration (ARMD) and AMD - Age-Related Macular Degeneration that is actively recruiting participants, run by Aptabio Therapeutics. The registered enrollment target is 68 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07330674, a Phase 1 study of Age Related Macular Degeneration (ARMD) and AMD - Age-Related Macular Degeneration, is actively recruiting participants, sponsored by Aptabio Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABF-101
Study Locations (1)
Texas
- Dallas Clinical Research Unit - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07330674
The ClinicalTrials.gov registry entry for NCT07330674 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptabio Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Age Related Macular Degeneration (ARMD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07330674 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07330674 about?
NCT07330674 is a clinical study titled "A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses". This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
What is the current status of trial NCT07330674?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2026-02. Estimated completion is 2027-12.
What conditions does trial NCT07330674 study?
This clinical trial studies the following conditions: Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration.
What interventions are being tested in trial NCT07330674?
The interventions under investigation include: Placebo (DRUG), ABF-101 (DRUG).
Who is sponsoring clinical trial NCT07330674?
This trial is sponsored by Aptabio Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07330674 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age Related Macular Degeneration (ARMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Age Related Macular Degeneration (ARMD)
All registered trials for this condition
AMD - Age-Related Macular Degeneration
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.